126
Participants
Start Date
August 5, 2024
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2025
T4090 0.2%
1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
T4090 0.3%
1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
Rhopressa®
1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
Alterman, Modi and Wolter Ophthalmic Surgeons, Poughkeepsie
Seidenberg Protzko Eye Associates, Havre de Grace
Emerson Clinical Research Institute, Falls Church
Piedmont Eye Center, Lynchburg
James D. Branch, MD, Winston-Salem
Coastal Research Associates, LLC, Roswell
East Coast Institute for Research, LLC, Jacksonville
Mild Florida Eye Center, Mt. Dora
Segal Drug Trials, Inc, Delray Beach
Shettle Eye Research, Inc., Largo
Total Eye Care, PA, Memphis
Houston Eye Associates, Houston
Glaucoma Associates of Texas, Dallas
Houston Eye Associates, Houston
DCT-Shah Research, LLC sba Discovery Clinical Trials, Mission
Keystone Research, Austin
Arizona Advanced Eye Research Institute, Glendale
United Medical Research Institute, Inglewood
Wolstan and Goldberg Eye Associates, Torrance
Global Research Management, Inc., Glendale
Eye Research Foundation, Newport Beach
Visionary Research Institute, Newport Beach
North Bay Eye Associates, Petaluma
Sacramento Eye Consultants, A Medical Corporation, Sacramento
Lead Sponsor
Laboratoires Thea
INDUSTRY